India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
The fresh capital will propel Cordance into its first-in-human clinical trial
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Renalyx will continue operating as an independent unit within the group
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
Subscribe To Our Newsletter & Stay Updated
